Pembrolizumab Receives Traditional FDA Approval for High TMB Solid Tumors
The FDA has changed pembrolizumab’s accelerated approval for solid tumors with high tumor mutational burden into full approval. The biomarker cutoff for treatment is now 13 mutations per megabase, up from 10. This update applies to TMB-H solid tumors.
The FDA has converted pembrolizumab’s accelerated approval for high tumor mutational burden solid tumors into traditional approval. This means the indication now has full rather than expedited regulatory status.
The biomarker cutoff for treatment is now 13 mutations per megabase, compared with the previous threshold of 10. The updated approval applies to solid tumors classified as TMB-H.
Patients whose tumors meet the revised TMB-H threshold may have a more firmly approved treatment option, while those below it may not qualify under this biomarker definition. Clinicians and testing laboratories could need to apply the new cutoff in treatment discussions. The change may also affect how biomarker-based cancer approvals are viewed by payers and drug developers, though real-world impact will depend on clinical practice and coverage decisions.